326914-10-7

Basic information

• Product Name: 5-[(Z)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE
• Synonyms: 5-[(Z)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE;SU11652
• CAS NO: 326914-10-7
• Molecular Formula: C22H27ClN4O2
• Molecular Weight: 414.93
• Mol File: 326914-10-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Very Slightly)
• CAS DataBase Reference: 5-[(Z)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[(Z)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE(326914-10-7)
• EPA Substance Registry System: 5-[(Z)-(5-CHLORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[2-(DIETHYLAMINO)ETHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE(326914-10-7)

Safety Data

• Hazardous Substances Data: 326914-10-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
SU11652 is utilized as a tyrosine kinase receptor inhibitor for its ability to target and inhibit the activity of specific tyrosine kinase receptors involved in cell signaling and growth. This makes it a valuable compound in the development of drugs for the treatment of various diseases, including cancer.
Used in Anti-angiogenic Therapy:
As an angiogenic inhibitor, SU11652 is employed in anti-angiogenic therapy to prevent the formation of new blood vessels that supply nutrients to tumors, thereby inhibiting their growth and spread. This application is particularly relevant in cancer treatment, where it can help control tumor progression and metastasis.
Used in Research Applications:
SU11652 is also used as a research tool in the study of tyrosine kinase receptor signaling pathways and angiogenesis. Its ability to inhibit these processes makes it a valuable compound for investigating the molecular mechanisms underlying various diseases and for identifying potential therapeutic targets.

Upstream product

• 100-36-7 N,N-diethylethylenediamine 
• 356069-14-2 5-(5-chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
• 253870-02-9 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
• 2199-59-9 ethyl (5-formyl-2,4-dimethyl-1H-pyrrole)-3-carboxylate 
• 86770-31-2 2-tert-butyl 4-ethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate 
• 110-89-4 piperidine 
• 17630-75-0 5-chloro-indolin-2-one 
• 356068-86-5 N-(2-(diethylamino)ethyl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide 

Relevant articles and documents

Combination therapy for the treatment of cancer

The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.

Pyrrole substituted 2-indolinone protein kinase inhibitors

The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.